Dark

Check out our API

PIRS
PIERIS PHARMACEUTICALS INC
stock NASDAQ

Inactive

Dec 13, 2024

13.60USD-15.685%(-2.53)51,728

Pre-market

0.00USD-100.000%(-16.13)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 28, 2022

08:00AM EST HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced it has appointed biopharmaceutical industry veteran Christopher Kiritsy to its Board of Directors. GlobeNewswire Inc

Jan 14, 2022

08:03AM EST Pieris Pharmaceuticals Announces Dosing Of First Patient In Phase 2 Gastric Cancer Trial Of 41BB/HER2 Bispecific Cinrebafusp Alfa Benzinga

Jan 3, 2022

07:07AM EST Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402 Benzinga

Nov 8, 2021

08:08AM EST Pieris Pharmaceuticals And Servier Announce Dosing Of First Patient In Phase 1/2 Trial Of 4-1BB/PD-L1 Bispecific PRS-344/S095012 Benzinga

Nov 2, 2021

10:52AM EDT Pieris Pharmaceuticals Q3 EPS $(0.24), Inline, Sales $4.06M Miss $5.32M Estimate Benzinga

10:41AM EDT Earnings Scheduled For November 2, 2021 Benzinga

Nov 1, 2021

11:00AM EDT Preview: Pieris Pharmaceuticals's Earnings Benzinga

Oct 27, 2021

11:56AM EDT Pieris Pharmaceuticals Granted European Patent Titled 'NOVEL PROTEINS SPECIFIC FOR ANGIOGENESIS' Benzinga

Oct 12, 2021

11:08AM EDT 3 Biotech Stocks to Watch Now Benzinga

Oct 6, 2021

08:14AM EDT Pieris Pharmaceuticals Appoints Thomas Bures As CFO And Ahmed Mousa As Chief Business Officer Benzinga

08:06AM EDT CORRECTION: Pieris Ticker Is 'PIRS' Benzinga

Sep 10, 2021

08:00AM EDT The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test Benzinga

Sep 2, 2021

08:20AM EDT The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab Benzinga

Sep 1, 2021

07:32AM EDT The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering Benzinga

Aug 31, 2021

08:15AM EDT The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical Benzinga

Aug 24, 2021

09:10AM EDT Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor Benzinga

Aug 4, 2021

07:26AM EDT Pieris Pharmaceuticals Q2 EPS $(0.25) Beats $(0.26) Estimate, Sales $3.29M Beat $2.07M Estimate Benzinga

04:10AM EDT Earnings Scheduled For August 4, 2021 Benzinga

Jul 6, 2021

04:08PM EDT Kenneth Griffin Discloses 5.2% Passive Stake In Pieris Pharmaceuticals Benzinga

Jun 25, 2021

11:09AM EDT Pieris Pharmaceuticals shares were trading higher after the company announced development of PRS-220 for idiopathic pulmonary fibrosis and a $17 million grant from the Bavarian government to accelerate program development for post-COVID pulmonary fibrosis. Benzinga

09:18AM EDT Pieris Stock Moves Higher On 14.2M Grant For PRS-220 In Post-COVID Pulmonary Fibrosis Benzinga

07:32AM EDT The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs Benzinga

07:02AM EDT Pieris Pharma Reports Development Of PRS-220 For Idiopathic Pulmonary Fibrosis; $17M Grant From Bavarian Gov't. To Accelerate Program Development For Post-COVID-19 Pulmonary Fibrosis Benzinga

Jun 24, 2021

08:02AM EDT Pieris Pharma Reports Received Orphan Drug Designation For Cinrebafusp Alfa To Treat Gastric Cancer Benzinga

Jun 15, 2021

01:17PM EDT Pieris Pharma US Patent & Trademark Office Abstract Filed For Co.'s 'Proteins specific for calcitonin gene-related peptide' Benzinga

01:17PM EDT Pieris Pharmaceuticals Granted U.S. Patent 'Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) which bind angiopoietin-2 (Ang-2)' Benzinga

May 27, 2021

08:24AM EDT The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs Benzinga

May 26, 2021

08:51AM EDT Benzinga Pro's Top 5 Stocks To Watch For Wednesday, May 26, 2021: AMC, PIRS, VMAC, MGM, BOX Benzinga

07:33AM EDT The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing Benzinga

May 25, 2021

11:06AM EDT Pieris Stock Surges on Development Pact with Genentech for Respiratory, Ophthalmology Settings Benzinga

08:06AM EDT Pieris Pharma Reports Respiratory, Ophthalmology Collab With Genentech Benzinga

May 20, 2021

08:14AM EDT Pieris Pharmaceuticals To Present At Jefferies 2021 Virtual Healthcare Conference Benzinga

May 17, 2021

07:34AM EDT Pieris Pharmaceuticals: Q1 Earnings Insights Benzinga

07:16AM EDT Pieris Pharmaceuticals Q1 EPS $(0.07) Beats $(0.17) Estimate, Sales $15.63M Beat $6.47M Estimate Benzinga

04:10AM EDT Earnings Scheduled For May 17, 2021 Benzinga

May 14, 2021

10:29AM EDT Earnings Preview: Pieris Pharmaceuticals Benzinga

May 6, 2021

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

Apr 26, 2021

08:07AM EDT Pieris Pharmaceuticals, Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342; Pieris To Receive Upfront Payment Of $10M And Is Entitled To Receive Up To ~$353M In Milestone Payments Benzinga

Mar 30, 2021

10:29AM EDT Pieris Pharmaceuticals shares were trading higher after the company reported FY20 earnings results. The company also announced that it entered into an agreement with AstraZeneca to non-exclusive anticalin platform license agreement. Benzinga

08:06AM EDT The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings Benzinga

07:27AM EDT UPDATE: In Connection With The Amended Agreements, AstraZeneca Will Acquire ~3.58M Shares Of Pieris' Stock At $2.79 Per Share Benzinga

07:24AM EDT Pieris Pharmaceuticals Announces The Co. And AstraZeneca Entered Into Amendment No. 1 To Non-exclusive Anticalin Platform License Agreement Along With Amendment No. 2 To License And Collaboration Agreement Dated May 2, 2017 Benzinga

07:18AM EDT Pieris Pharmaceuticals: Q4 Earnings Insights Benzinga

07:06AM EDT Pieris Pharmaceuticals FY20 EPS $(0.68), Down From $(0.56) YoY, Sales $29.323M, Down From $46.28M YoY Benzinga

04:04AM EDT Earnings Scheduled For March 30, 2021 Benzinga

Mar 29, 2021

10:06AM EDT Pieris Pharmaceuticals's Earnings Outlook Benzinga

Mar 27, 2021

01:01PM EDT The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week Benzinga

Mar 25, 2021

10:31AM EDT Pieris shares were trading higher after the company announced Seagen has made a strategic equity investment in Pieris as part of an ongoing collaboration between the companies. Benzinga

08:04AM EDT UPDATE: Seagen Made Equity Investment In Pieris Via Purchase Of 3.7M Shares At $3.51/Share Benzinga

08:03AM EDT Pieris Reports Amendment To Existing Immuno-oncology Multi-Target Collab With Seagen, $13M Strategic Investment By Seagen Benzinga

Mar 16, 2021

05:33AM EDT Pieris Pharmaceuticals Awarded U.S. Patent 10,947,284 'Fusion molecules' Benzinga

Feb 23, 2021

03:57PM EST Pieris Pharmaceuticals Granted U.S. Patent Titled 'Human tear lipocalin muteins which specifically bind lymphocyte activation gene-3 (LAG3) and method of use thereof to stimulate an immune response' Benzinga

Jan 26, 2021

01:54PM EST Pieris Pharmaceuticals Granted U.S. Patent Titled 'Tear lipocalin muteins binding IL-4 r alpha' Benzinga

Jan 19, 2021

08:07AM EST FDA Lifts Partial Clinical Hold On PRS-343 Phase 1 Studies Benzinga

Dec 15, 2020

03:12PM EST '$PIRS granted US Patent #10865250 for "Anti-cancer fusion polypeptide". For the treatment/prevention of a variety of tumors. No Press Release Yet.' - Tweet From Patent_Stocks Benzinga

Nov 4, 2020

07:58AM EST Pieris Pharmaceuticals: Q3 Earnings Insights Benzinga

07:10AM EST Pieris Pharmaceuticals Q3 EPS $(0.26) Misses $(0.13) Estimate Benzinga

04:41AM EST Earnings Scheduled For November 4, 2020 Benzinga

Aug 10, 2020

08:10AM EDT Recap: Pieris Pharmaceuticals Q2 Earnings Benzinga

07:44AM EDT Pieris Pharmaceuticals Q2 EPS $(0.09) Beats $(0.17) Estimate, Sales $11.25M Beat $7.76M Estimate Benzinga

06:46AM EDT Pieris Pharma and Eli Lilly to Evaluate the Combination of PRS-343 With Ramucirumab and Paclitaxel in Gastric Cancer Benzinga

04:10AM EDT Earnings Scheduled For August 10, 2020 Benzinga

Jul 23, 2020

08:07AM EDT Pieris Pharmaceuticals Announces Oral Presentation Of Phase 1 Data For 4-1BB/HER2 Bispecific PRS-343 At European Society For Medical Oncology (ESMO) Virtual Congress 2020 September 20 Benzinga

Jul 21, 2020

07:27PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of PR Newswire

06:00AM EDT A Peek Into The Markets: US Stock Futures Gain Ahead Of Earnings Benzinga

Jul 20, 2020

04:08PM EDT Pieris Pharmaceuticals Announces Partial Clinical Hold On PRS-343 Benzinga

Share